Table 2.

Efficacy Parameters in the DURATION Clinical Development Program

		DURATION-1		DURATION-5		DURATION-2			DURATION-3
	ExQW range	ExQW	ExBID	ExQW	ExBID	ExQW	Sitagliptin	Pioglitazone	ExQW	Glargine
Glycemic control
HbA1c (%) to goal
<7%	58–71	71a	51ab	58	30b	59	31b	44b	60	48b
≤6.5%	39–45	45a	38a	41	16b	39	16b	27b	43a	28ab
End point mean HbA1c (%)	6.4–7.2	6.4	6.8	7.1	7.7	7.2	7.7	7.4	6.8	7.0
Markers of CV risk
Δ SBP (mm Hg)	−2.9 to −4.7	−4.7c	−3.4c	−2.9c	−1.2	−3.6c	+0.2b	−1.6	−3.0c	−1.0
ΔTotal cholesterol (mg/dL)	−0.6 to−15	−11.9c	−3.8b	−15c	+0.6b	−0.6	+3.1	+6.2c	−4.6c	−1.5
Δ LDL cholesterol (mg/dL)	−1 to −6	−4.9c	+1.2b	−6.4c	+2.8b	−1.0	+1.8	+1.8	−1.9	+1.5
Δ HDL cholesterol (mg/dL)	−1 to +2	−0.9	−1.3c	0	+1.3	+2.0c	+2.0c	+6.2bc	0	+0.4
Δ Triglycerides (%)	−4 to −15	−15c	−11c	−6	−1	−5	−5	−16bc	−4	−11c

^aData on file at Amylin Pharmaceuticals.

^bTreatment difference versus ExQW, P<0.05.

^cSignificant difference versus baseline, P<0.05.

CV, cardiovascular; ExBID, exenatide twice daily; ExQW, exenatide once weekly; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.